The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease

Journal of Clinical Investigation

Volumn 121, Issue 2, 2011, Pages 476-483

  Munoz Sanjuan, Ignacio ^a   Bates, Gillian P ^b  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATOMOXETINE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CITALOPRAM; CREATINE; DIMEBON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LITHIUM; MEMANTINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; MODAFINIL; PRIDOPIDINE; SIRTUIN 1; SYNAPTOPHYSIN; TETRABENAZINE; VALPROATE SEMISODIUM;

CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN HOMEOSTASIS; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE THERAPY; HUMANS; HUNTINGTON DISEASE;

EID: 79551554590     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45364     Document Type: Review

References (128)

1. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115(6):1449-1457.
2. Spinney L. Uncovering the true prevalence of Huntington's disease. Lancet Neurol. 2010;9(8):760-761.
3. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-318.
4. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90(3):905-981.
5. Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397-408.
6. Biglan KM, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763-1772.
7. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62(12):1341-1346. (Pubitemid 350180721)
8. Duff K, et al. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci. 2010;22(2):196-207.
9. Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs. 2010;70(5):561-571.
10. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. 2009;2009(3):CD006456.
11. Paulsen JS, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3-4):201-207.
12. Pavese N, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis. 2010;37(2):356-361.
13. Schippling S, et al. Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol Psychiatry. 2009;65(11):959-965.
14. Thu DC, et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain. 2010;133(pt 4):1094-1110.
15. Hult S, Schultz K, Soylu R, Petersen A. Hypothalamic and neuroendocrine changes in Huntington's disease. Curr Drug Targets. 2010;11(10):1237-1249.
16. Truant R, Atwal RS, Desmond C, Munsie L, Tran T. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J. 2008;275(17):4252-4262.
17. Jacobsen JC, et al. An ovine transgenic Huntington's disease model. Hum Mol Genet. 2010;19(10):1873-1882.
18. Graham RK, et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol Dis. 2006;21(2):444-455.
19. Heng MY, Detloff PJ, Albin RL. Rodent genetic models of Huntington disease. Neurobiol Dis. 2008;32(1):1-9.
20. von Horsten S, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet. 2003;12(6):617-624.
21. Cha JH, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A. 1998;95(11):6480-6485.
22. Graham RK, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125(6):1179-1191.
23. Bjorkqvist M, et al. Progressive alterations in the hypothalamic- pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet. 2006;15(10):1713-1721.
24. Johnson MA, Rajan V, Miller CE, Wightman RM. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J Neurochem. 2006;97(3):737-746.
25. Luthi-Carter R, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000;9(9):1259-1271.
26. Strand AD, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci. 2007;27(43):11758-11768.
27. Tabrizi SJ, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000;47(1):80-86.
28. Tsang TM, et al. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res. 2006;5(3):483-492.
29. Slow EJ, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12(13):1555-1567.
30. Gray M, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28(24):6182-6195.
31. Buckley NJ, Johnson R, Zuccato C, Bithell A, Cattaneo E. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol Dis. 2010;39(1):28-39.
32. Zuccato C, et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J Neurosci. 2007;27(26):6972-6983.
33. Runne H, et al. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci. 2008;28(39):9723-9731.
34. Yin D, et al. Striatal volume differences between non-human and human primates. J Neurosci Methods. 2009;176(2):200-205.
35. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp Neurol. 2009;219(2):385-397.
36. Komssi S, Kahkonen S. The novelty value of the combined use of electroencephalography and transcranial magnetic stimulation for neuroscience research. Brain Res Rev. 2006;52(1):183-192. (Pubitemid 44051536)
37. Norra C. Challenge tests of monoaminergic systems: neurophysiological aspects. Clin EEG Neurosci. 2007;38(2):66-73. (Pubitemid 46866504)
38. Paulsen JS, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-880.
39. Tabrizi SJ, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801.
40. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev. 2009;2009(3):CD006455.
41. Bloch J, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther. 2004;15(10):968-975.
42. Blackwell AD, Paterson NS, Barker RA, Robbins TW, Sahakian BJ. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology (Berl). 2008;199(1):29-36.
43. Schiefer J, et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 2004;1019(1-2):246-254.
44. Kieburtz K, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010;67(2):154-160.
45. Chou SY, et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem. 2005;93(2):310-320.
46. Hockly E, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003;100(4):2041-2046.
47. Thomas EA, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A. 2008;105(40):15564-15569.
48. Giampa C, et al. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci. 2009;29(5):902-910.
49. DeMarch Z, Giampa C, Patassini S, Bernardi G, Fusco FR. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis. 2008;30(3):375-387.
50. Li M, Huang Y, Ma AA, Lin E, Diamond MI. Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis. 2009;36(3):413-420.
51. Apostol BL, et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci. 2008;39(1):8-20.
52. Palazuelos J, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain. 2009;132(pt 11):3152-3164.
53. Canals JM, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci. 2004;24(35):7727-7739.
54. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem. 2008;105(2):369-379. (Pubitemid 351490006)
55. Zuccato C, et al. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res. 2005;52(2):133-139.
56. Ebert AD, Barber AE, Heins BM, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol. 2010;224(1):155-162.
57. McBride JL, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006;103(24):9345-9350.
58. Gagnon KT. HD Therapeutics - CHDI Fifth Annual Conference. IDrugs. 2010;13(4):219-223.
59. Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol. 2010;225(1):74-84.
60. Ryan AB, Zeitlin SO, Scrable H. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis. Neurobiol Dis. 2006;24(2):419-427.
61. Steffan JS, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000;97(12):6763-6768.
62. Bae BI, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005;47(1):29-41.
63. McConoughey SJ, et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med. 2010;2(9):349-370.
64. Mastroberardino PG, et al. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 2002;9(9):873-880.
65. Jiang H, et al. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis. 2006;23(3):543-551. (Pubitemid 44234090)
66. Klevytska AM, Tebbenkamp AT, Savonenko AV, Borchelt DR. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease. J Neuropathol Exp Neurol. 2010;69(4):396-404.
67. Hay DG, et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet. 2004;13(13):1389-1405.
68. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127(1):59-69.
69. Auerbach W, et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet. 2001;10(22):2515-2523.
70. Reiner A, Dragatsis I, Zeitlin S, Goldowitz D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol. 2003;28(3):259-276.
71. Hampel H, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560-574.
72. Andre VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci Ther. 2010;16(3):163-178.
73. Brandt J, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci. 1990;2(1):20-27.
74. Brooks DJ, et al. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse. 2008;62(9):671-681.
75. Van Laere K, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med. 2010;51(9):1413-1417.
76. Chaturvedi RK, et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet. 2009;18(16):3048-3065.
77. Napolitano M, et al. Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. Neurobiol Dis. 2004;15(2):407-414.
78. Rosenstock TR, Duarte AI, Rego AC. Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench. Curr Drug Targets. 2010;11(10):1218-1236.
79. Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res. 2005;1031(1):82-89.
80. Taylor-Robinson SD, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord. 1996;11(2):167-173.
81. Hicks SL, Robert MP, Golding CV, Tabrizi SJ, Kennard C. Oculomotor deficits indicate the progression of Huntington's disease. Prog Brain Res. 2008;171:555-558.
82. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry. 2008;79(2):130-135. (Pubitemid 351236541)
83. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology. 1999;53(4):806-812.
84. Krainc D. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol. 2010;67(4):388-392.
85. Davies JE, Sarkar S, Rubinsztein DC. The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. BMC Biochem. 2007;8(suppl 1):S2.
86. Martinez-Vicente M, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci. 2010;13(5):567-576.
87. Williams A, et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol. 2008;4(5):295-305. (Pubitemid 351550888)
88. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci. 2010;13(7):805-811.
89. Pan J, Song E, Cheng C, Lee MH, Yeung SC. Farnesyltransferase inhibitors-induced autophagy: alternative mechanisms? Autophagy. 2009;5(1):129-131.
90. Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther. 2006;6(3):313-319.
91. Wu IC, Ohsawa I, Fuku N, Tanaka M. Metabolic analysis of 13C-labeled pyruvate for noninvasive assessment of mitochondrial function. Ann N Y Acad Sci. 2010;1201:111-120.
92. Yang L, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem. 2009;109(5):1427-1439.
93. Oliveira JM. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J Neurochem. 2010;114(1):1-12.
94. Pandey M, Mohanakumar KP, Usha R. Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease. J Bioenerg Biomembr. 2010;42(3):217-226.
95. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem. 2008;283(37):25628-25637.
96. Okamoto S, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15(12):1407-1413.
97. Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci. 2009;1173(suppl 1):E10-E19.
98. Chiang MC, et al. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet. 2010;19(20):4043-4058.
99. Weydt P, et al. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener. 2009;4:3.
100. van Oostrom JC, Dekker M, Willemsen AT, de Jong BM, Roos RA, Leenders KL. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur J Neurol. 2009;16(2):226-231.
101. Chen-Plotkin AS, et al. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiol Dis. 2006;22(2):233-241.
102. Cornett J, Smith L, Friedman M, Shin JY, Li XJ, Li SH. Context-dependent dysregulation of transcription by mutant huntingtin. J Biol Chem. 2006;281(47):36198-36204.
103. Jiang H, Nucifora FC Jr, Ross CA, DeFranco DB. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet. 2003;12(1):1-12.
104. Zuccato C, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493-498. (Pubitemid 32679077)
105. Zuccato C, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35(1):76-83.
106. Kleiman RJ, et al. Chronic suppression of PDE10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission and signaling pathways implicated in Huntington's Disease. J Pharmacol Exp Ther. 2011;336:64-76.
107. Steffan JS, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413(6857):739-743.
108. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav. 2009;94(1):148-153.
109. Ferrante RJ, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003;23(28):9418-9427.
110. Joshi PR, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci. 2009;29(8):2414-2427.
111. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11-26.
112. Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J Neurochem. 2010;112(3):755-761.
113. Wang H, Chen X, Li Y, Tang TS, Bezprozvanny I. Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener. 2010;5:18.
114. Petrikis P, Andreou C, Piachas A, Bozikas VP, Karavatos A. Treatment of Huntington's disease with galantamine. Int Clin Psychopharmacol. 2004;19(1):49-50.
115. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009;29(10):3200-3205.
116. Huang K, et al. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2010;40(1):207-215.
117. Cummings DM, et al. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci. 2009;29(33):10371- 10386.
118. Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. The corticostriatal pathway in Huntington's disease. Prog Neurobiol. 2007;81(5-6):253-271.
119. Kloppel S, et al. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience. 2009;164(1):205-219.
120. Milnerwood AJ, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010;65(2):178-190.
121. Tallaksen-Greene SJ, Janiszewska A, Benton K, Ruprecht L, Albin RL. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp Neurol. 2010;225(2):402-407.
122. Miller BR, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience. 2008;153(1):329-337.
123. Sari Y, Prieto AL, Barton SJ, Miller BR, Rebec GV. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. J Biomed Sci. 2010;17:62.
124. Moro E, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol. 2004;56(2):290-294. (Pubitemid 39037926)
125. Fawcett AP, Moro E, Lang AE, Lozano AM, Hutchison WD. Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. Mov Disord. 2005;20(3):371-377.
126. Eidelberg D, Surmeier DJ. Brain networks in Huntington disease. J Clin Invest. 2011;121(2):484-492.
127. Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121(2):493-499.
128. Sah DWY, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest. 2011;121(2):500-507.